Investor Alert

New York Markets Open in:

press release

Nov. 2, 2021, 4:01 p.m. EDT

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results

– Third Quarter 2021 Revenue of $23.2 Million, Including QINLOCK® (ripretinib) Net Product Revenue of $21.7 Million –  – Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line Gastrointestinal Stromal Tumor (GIST) Expected in the Fourth Quarter of 2021 – – Approval from the European Medicines Agency (EMA) for QINLOCK Expected in the Fourth Quarter of 2021 –  – Initiation of the Phase 3 MOTION Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) Expected in the Fourth Quarter of 2021; Vimseltinib Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) –

WALTHAM, Mass., (BUSINESS WIRE) -- Deciphera Pharmaceuticals, Inc. /zigman2/quotes/203556943/composite DCPH +4.13% today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

“In the third quarter, we made tremendous progress expanding the reach of QINLOCK for patients with GIST around the world. In addition to obtaining the approval for this important medicine in Switzerland and Taiwan, we also received a positive CHMP opinion for QINLOCK in the EU, with approval expected before the end of the year. Finally, we remain on track to report top-line results from the Phase 3 INTRIGUE study in second-line GIST later this quarter.”

Mr. Hoerter continued, “At the European Society for Medical Oncology (ESMO) Congress 2021, we shared very encouraging data from both the vimseltinib and rebastinib programs demonstrating significant clinical activity in two diseases with high unmet medical needs. We plan to initiate the Phase 3 MOTION study of vimseltinib in tenosynovial giant cell tumor this quarter and expect to initiate a Phase 3 study of rebastinib in combination with paclitaxel in platinum-resistant ovarian cancer next year. The body of scientific evidence continues to build supporting the potential of our first-in-class ULK inhibitor, DCC-3116, to address a broad spectrum of cancers in which autophagy is upregulated and believed to play an important role in tumor growth and survival. The Phase 1/2 study of DCC-3116 is on track and, with the first-in-class program in this field, we are well positioned to explore the full potential of inhibiting autophagy in cancer.”

Third Quarter 2021 Highlights and Upcoming Milestones

  • QINLOCK(ripretinib)

  • Vimseltinib

  • Rebastinib

  • DCC-3116

Third Quarter Financial Results

  • Revenue: Total revenue for the third quarter of 2021 was $23.2 million, which includes $21.7 million of net product revenue from sales of QINLOCK and $1.5 million of collaboration revenue comprised primarily of QINLOCK supply and royalty revenue under our license agreement with Zai Lab. Total revenue for the third quarter of 2020 was $15.5 million, which included $15.2 million of net product revenue from sales of QINLOCK and $0.3 million of collaboration revenue.

  • Cost of Sales : Cost of sales was $0.9 million in the third quarter of 2021, which includes $0.2 million in cost of net product revenue for QINLOCK and $0.7 million in cost of collaboration revenue. Cost of sales was $0.1 million for the third quarter of 2020. Deciphera does not expect that the cost of sales as a percentage of net product sales of QINLOCK will increase significantly after the Company has sold all zero cost inventories and commenced the sales of inventories which will reflect the full cost of manufacturing. The Company expects to continue to sell the zero cost inventories of QINLOCK in the U.S. during 2021 and into 2022.

  • R&D Expenses: Research and development expenses for the third quarter were $66.4 million, compared to $49.2 million for the same period in 2020. The increase was primarily due to personnel and preclinical costs, and a $4.0 million up-front payment to Sprint Bioscience (Sprint) pursuant to the terms of the agreement with Sprint to exclusively in-license worldwide rights to a research-stage program targeting VPS34, and an increase in clinical trial expenses related to start-up activities for the planned Phase 3 MOTION study of vimseltinib and Phase 1b/2 study of QINLOCK in combination with binimetinib. Non-cash, stock-based compensation was $5.4 million and $4.5 million for the third quarters of 2021 and 2020, respectively.

  • SG&A Expenses: Selling, general, and administrative expenses for the third quarter of 2021 were $35.5 million, compared to $30.1 million for the same period in 2020. The increase was primarily due to personnel costs as well as external spend related to professional fees, including those associated with establishing a targeted commercial infrastructure and commercial preparedness in key European markets to support a launch of QINLOCK in Europe, if approved. Non-cash, stock-based compensation was $6.4 million and $5.3 million for the third quarters of 2021 and 2020, respectively.

  • Net Loss: For the third quarter of 2021, Deciphera reported a net loss of $79.8 million, or $1.37 per share, compared with a net loss of $63.7 million, or $1.13 per share, for the same period in 2020. The increase in net loss was primarily a result of increased R&D expenses, as described above, partially offset by increased sales volume in the U.S.

  • Cash Position: As of September 30, 2021, cash, cash equivalents, and marketable securities were $392.2 million, compared to $451.0 million as of June 30, 2021. Based on its current operating plans, Deciphera expects its current cash, cash equivalents, and marketable securities together with anticipated product, royalty, and supply revenues, excluding any potential future milestone payments under the Zai License Agreement, will enable the Company to fund its operating and capital expenditures into the first half of 2023.

Conference Call and Webcast

Deciphera will host a conference call and webcast to discuss this announcement today, November 2, 2021, at 4:30 PM ET. To access the live call by phone please dial (866) 930-5479 (domestic) or (409) 216-0603 (international); the conference ID is 8178994. A live audio webcast of the event may also be accessed through the “Investors” section of Deciphera’s website at www.deciphera.com . A replay of the webcast will be available for 30 days following the event.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, Hong Kong, Switzerland, Taiwan, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations and timing regarding top-line data from our Phase 3 INTRIGUE study in second-line GIST, plans to initiate a phase 1b/2 study of QINLOCK with a MEK inhibitor in post-imatinib GIST patients, potential EMA approval of QINLOCK for the treatment of fourth-line GIST, plans to initiate pivotal studies for vimseltinib in TGCT patients and for the rebastinib/paclitaxel combination, subject to discussions with regulators, the potential benefits of fast track designation from the FDA, the potential of DCC-3116 to address a broad spectrum of cancers in which autophagy is upregulated and our timing for initial data from the dose escalation portion of the phase 1 study of DCC-3116, the company’s leading position in the development of regulators of autophagy for the potential treatment of cancer, and cash runway expectations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the severity and duration of the impact of COVID-19 on our business and operations, our ability to successfully demonstrate the efficacy and safety of our drug candidates and in additional indications for our existing drug, the preclinical or clinical results for our product candidates, which may not support further development of such product candidates, our ability to manage our reliance on sole-source third parties such as our third party drug substance and drug product contract manufacturers, comments, feedback and actions of regulatory agencies, our ability to commercialize QINLOCK and execute on our marketing plans for any drugs or indications that may be approved in the future, our ability to build and scale our operations to support growth in additional geographies, the inherent uncertainty in estimates of patient populations, competition from other products, our ability to obtain and maintain reimbursement for any approved product and the extent to which patient assistance programs are utilized, our ability to comply with healthcare regulations and laws, our ability to obtain, maintain and enforce our intellectual property rights, any or all of which may affect the initiation, timing and progress of clinical studies and the timing of and our ability to obtain additional regulatory approvals, and other risks identified in our Securities and Exchange Commission (SEC) filings, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.


Deciphera Pharmaceuticals, Inc.
  September 30, 2021   December 31, 2020
Current assets:      
Cash and cash equivalents $ 53,189      $ 135,897   
Short-term marketable securities 289,081      416,033   
Accounts receivable, net 18,049      13,896   
Inventory 7,253      5,716   
Prepaid expenses and other current assets 17,722      12,489   
Total current assets 385,294      584,031   
Long-term marketable securities 49,926      9,375   
Long-term investments—restricted 3,102      3,102   
Property and equipment, net 10,820      9,583   
Operating lease assets 34,276      36,341   
Total assets $ 483,418      $ 642,432   
Liabilities and Stockholders' Equity      
Current liabilities:      
Accounts payable $ 13,502      $ 12,308   
Accrued expenses and other current liabilities 59,625      55,227   
Operating lease liabilities 2,662      2,457   
Total current liabilities 75,789      69,992   
Operating lease liabilities, net of current portion 27,172      28,764   
Total liabilities 102,961      98,756   
Commitments and contingencies (Note 8)      
Stockholders' equity:      
Common stock, $0.01 par value per share; 125,000,000 shares authorized; 58,327,889 shares and 57,596,144 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 583      576   
Additional paid-in capital 1,345,746      1,297,557   
Accumulated other comprehensive income (loss) 165      11   
Accumulated deficit (966,037)     (754,468)  
Total stockholders' equity 380,457      543,676   
Total liabilities and stockholders' equity $ 483,418      $ 642,432   
Deciphera Pharmaceuticals, Inc.
  Three Months Ended September 30,   Nine Months Ended September 30,
  2021   2020   2021   2020
Product revenues, net $ 21,682      $ 15,164      $ 63,692      $ 19,989   
Collaboration revenues 1,538      285      8,257      2,612   
Total revenues 23,220      15,449      71,949      22,601   
Cost and operating expenses:              
Cost of sales 917      90      2,414      98   
Research and development 66,444      49,213      182,109      146,682   
Selling, general, and administrative 35,527      30,143      99,102      84,012   
Total cost and operating expenses 102,888      79,446      283,625      230,792   
Loss from operations (79,668)     (63,997)     (211,676)     (208,191)  
Other income (expense):              
Interest and other income, net (170)     296      107      4,442   
Total other income (expense), net (170)     296      107      4,442   
Net loss $ (79,838)     $ (63,701)     $ (211,569)     $ (203,749)  
Net loss per share—basic and diluted $ (1.37)     $ (1.13)     $ (3.65)     $ (3.68)  
Weighted average common shares outstanding—basic and diluted 58,107,611      56,390,748      57,948,612      55,296,775   


View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006042/en/

SOURCE: Deciphera Pharmaceuticals, Inc.

Investor Relations:
Jen Robinson
Deciphera Pharmaceuticals, Inc.
781-906-1112 Media:
David Rosen
Argot Partners


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2021

US : U.S.: Nasdaq
$ 11.84
+0.47 +4.13%
Volume: 1.07M
May 20, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$784.00 million
Rev. per Employee


Partner Center

Link to MarketWatch's Slice.